Definium Therapeutics, Inc. Common Shares (DFTX) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "DFTX"
      ],
      "issuer_cik": "0001813814",
      "owner_cik": "0001516354",
      "accession_number": "0001104659-26-112058",
      "form_type": "4",
      "filing_date": "2026-09-29",
      "period_of_report": "2026-09-25",
      "issuer_name": "Definium Therapeutics, Inc.",
      "issuer_trading_symbol": "DFTX",
      "owner_name": "Roberts Brandi",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Financial Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Shares",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-09-25",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 3377,
      "transaction_price_per_share": 36.57,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 394528,
      "transaction_value": 123496.89,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 30, 2025."
        },
        {
          "id": "F2",
          "description": "The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2026 at prices ranging from $36.24 to $36.98. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
        }
      ]
    },
    {
      "tickers": [
        "DFTX"
      ],
      "issuer_cik": "0001813814",
      "owner_cik": "0001897557",
      "accession_number": "0001104659-26-112062",
      "form_type": "4",
      "filing_date": "2026-09-29",
      "period_of_report": "2026-09-25",
      "issuer_name": "Definium Therapeutics, Inc.",
      "issuer_trading_symbol": "DFTX",
      "owner_name": "Barrow Robert",
      "is_director": true,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Executive Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Shares",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-09-25",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 31550,
      "transaction_price_per_share": 36.57,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 2213090,
      "transaction_value": 1153783.5,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."
        },
        {
          "id": "F2",
          "description": "The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2026 at prices ranging from $36.24 to $36.98. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.